FDA Approval for C-Pulse US Clinical Trial
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Venture capital fund
Every published round Three Arch Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Three Arch Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Three Arch Partners, as distinct from the investments it has made.
Companies Three Arch Partners has backed that another company then bought. An exit for the holding, not a deal Three Arch Partners did.
| Name | Role | Sources |
|---|---|---|
| Dr Richard Lin | Partner | GBS Ventures (20 Sep 2007), GBS Ventures (13 Jun 2006) |
Stories naming Three Arch Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Sunshine Heart announced Dr Richard Lin will step down from its board at the November 2007 AGM, with Three Arch Partners nominating Dr Conrad Wang to stand for election in his place.
Sunshine Heart says co-founder Crispin Marsh will swap his executive corporate affairs role for a non-executive board seat from mid-2006, as the medical device maker brings in senior staff including a new COO.